Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the
presence of autoantibodies against nuclear antigens, immune complex deposition, and …

OBJECTIVE: To present a pooled analysis of the efficacy of rituximab from European cohorts
diagnosed with biopsy-proven lupus nephropathy (LN) who were treated with rituximab …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV
lupus nephritis (LN). Methods Patients were randomized 1: 1: 1 to receive placebo, 400 mg …

Objective A number of open‐label studies have suggested the potential benefit of rituximab
(RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled …

Background The treatment of lupus nephritis (LN) remains problematic because the current
treatment regimen based on unspecific immunosuppressants such as steroids …

Haematological manifestations in systemic lupus erythematosus (SLE) are frequently
observed. They are diverse and range from mild to severe. Therefore, different treatment …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

The treatment of lupus nephritis has changed significantly over the past decade in large part
because of data from well-conducted randomized clinical trials. The concept of two phases …

Increased understanding of the molecular mechanisms underlying the pathogenenesis of
autoimmune rheumatic diseases has led to targeted biological treatments that modulate …